Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BG-68501 in Advanced Solid Tumors
NCT06257264Phase 1Active, not recruiting
- Sponsor
- BeiGene
- Start
- Mar 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of BG-68501 in solid tumor, breast cancer, ovarian cancer and 7 more (5 arms), sponsored by BeiGene. Primary endpoints: Number of Participants with Adverse Events and Serious Adverse Events, Maximum Tolerated Dose or Maximum Administered Dose and 2 more. Started Mar 2024; status: active, not recruiting.
02
Drugs
BG-68501
03
Conditions
solid tumorbreast cancerovarian cancerendometrial cancer (EC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06257264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06257264.